No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Mar 5, 2024
On 5 March 2024, a study published in Modern Rheumatology found that LG Chem's LBEC0101, the biosimilar of etanercept, matches up to the reference product in terms of effectiveness and safety in the real-world treatment of rheumatoid arthritis. This evidence was...
Mar 5, 2024
Johnson and Johnson (J&J) and Janssen have filed a Motion to Dismiss a class action brought by several US health insurers alleging the companies unlawfully delayed biosimilar competition for Stelara® (ustekinumab) in the US. J&J/Janssen argue that the alleged...
Mar 5, 2024
On 5 March 2024, the FDA approved Fresenius Kabi’s Tyenne® (tocilizumab), biosimilar to Genentech’s/Roche’s Actemra®, for the treatment of rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic...
Mar 5, 2024
On 5 March 2024, the FDA approved the first denosumab biosimilars in the US in Sandoz's Wyost® and Jubbonti®. The biosimilars are interchangeable with, and approved for all indications of, Amgen’s Xgeva® and Prolia® respectively. The US launch date for the newly...
Mar 5, 2024
Novo Nordisk announced the results of its Ozempic® (semaglutide 1.0mg) FLOW study kidney outcomes. In this study, semaglutide 1.0 mg was compared to placebo as an adjunct to standard of care for prevention of progression of kidney impairment and risk of kidney and...
Mar 5, 2024
On 5 March 2024, the Times of India reported that Roche launched Vabysmo® (faricimab) in India for the treatment of age-related macular degeneration (nAMD) and diabetic macular edema (DME). Vabysmo® was first approved in the US by the FDA in January 2022 and is...
Mar 5, 2024
A paper published in Nature Communications on 5 March 2024 regarding a Phase II clinical trial sponsored by Arcagy-GINECO showed that FKB238 (bevacizumab biosimilar) + olaparib + durvalumab combination showed better survival for treatment of patients with relapsed...
Mar 4, 2024
On 4 March 2024, Sandoz announced the completion of its acquisition of biosimilar CIMERLI® (ranibizumab) from Coherus BioSciences. This VEGF inhibitor ranibizumab was approved by the FDA on 2 August 2022 and is indicated for the treatment of retinal diseases. The...
Mar 4, 2024
Amgen announced that Wezlana™ (ustekinumab injection) and Wezlana™ (ustekinumab for injection, solution for intravenous infusion), biosimilar to Janssen’s Stelara®, is now available in Canada. Wezlana™ is the first biosimilar to be approved by Health Canada for all...
Mar 4, 2024
Biocon announced a settlement with Regeneron and Bayer under which it can launch its Yesafili® (aflibercept), biosimilar to Regeneron’s Eylea®, in Canada from 1 July 2025. The settlement resolves multiple patent infringement proceedings in the Federal Court of Canda...
Mar 4, 2024
On 4 March 2024, Sandoz announced that Health Canada approved Wyost® as biosimilar to, and for all indications of, Amgen’s Xgeva® (denosumab). This follows the Canadian approval of Sandoz’s Jubbonti®, biosimilar to Amgen’s Prolia® (denosumab) in February 2024 for...
Mar 4, 2024
On 4 March 2024, Merck Sharp & Dohme, LLC filed petitions for inter partes review against four Johns Hopkins University (JHU) patents relating to methods of treatment using pembrolizumab in patients whose cancers have a genetic instability called microsatellite...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.